Therapy resistance remains a major problem in estrogen receptor-α (ERα)-positive breast cancer. A subgroup of ERα-positive breast cancer is characterized by mosaic presence of a minor population of ERα-negative cancer cells expressing the basal cytokeratin-5 (CK5). These CK5-positive cells are therapy resistant and have increased tumor-initiating potential. Although a series of reports document induction of the CK5-positive cells by progestins, it is unknown if other 3-ketosteroids share this ability. We now report that glucocorticoids and mineralocorticoids effectively expand the CK5-positive cell population. CK5-positive cells induced by 3-ketosteroids lacked ERα and progesterone receptors, expressed stem cell marker, CD44, and displayed increased clonogenicity in soft agar and broad drug-resistance in vitro and in vivo. Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin. Prolactin also suppressed 3-ketosteroid induction of CK5+ cells in T47D xenografts in vivo. Survival analysis with recursive partitioning in node-negative ERα-positive breast cancer using quantitative CK5 and BCL6 mRNA or protein expression data identified patients at high or low risk for tumor recurrence in two independent patient cohorts. The data provide a mechanism by which common pathophysiological or pharmacologic elevations in glucocorticoids or other 3-ketosteroids may adversely affect patients with mixed ERα+/CK5+ breast cancer. The observations further suggest a cooperative diagnostic utility of CK5 and BCL6 expression levels and justify exploring efficacy of inhibitors of BCL6 and 3-ketosteroid receptors for a subset of ERα-positive breast cancers.
INTRODUCTION
Estrogen receptor-α positive (ERα+) disease comprises 70-80% of all newly diagnosed invasive breast carcinomas.
1,2 Despite widespread use of adjuvant anti-estrogen and chemotherapy, approximately one in four patients with ERα+ breast cancer will experience recurrence of therapy-resistant disease. 3, 4 Although selection for cancer cells with genomic or epigenetic alterations may underlie a portion of subsequent therapy-resistant disease, recurrence of some ERα+ breast cancers may alternatively result from the expansion of a pre-existing cell population that is intrinsically resistant to adjuvant therapy. 5 Tumor marker-based classification of ERα+ breast cancer into therapy-relevant subtypes remains an ongoing effort. Protein expression phenotyping of breast cancer includes hormone receptor status (ERα, progesterone receptor (PR)), Her2 status, proliferation status (Ki67) and basal cytokeratin-5 (CK5) expression. 6 Luminal A breast cancer (ERα+/CK5-/Her2-/Ki67 low ) is associated with favorable outcome with adjuvant anti-estrogen therapy. Luminal B breast cancer (ERα+/CK5-/Her2 ± /Ki67 high ) confers poor prognosis but patients do benefit from anti-estrogen therapy. An emerging subgroup of ERα+ breast cancer display predominantly ERα+/CK5 − cells and mosaic presence of a subpopulation of ERα − /CK5+ cells, referred to as 'mixed luminal and basal' 7 or 'Luminobasal' breast cancer. 8, 9 These tumors are thought to develop resistance to common adjuvant therapies through expansion of the ERα − /CK5+ cell population. [8] [9] [10] CK5 is expressed in baso-luminal precursor cells of healthy breast epithelia and is a commonly used marker for tumors within the basal-like subtype of triple-negative breast cancer (TNBC) but has generally been considered absent in ERα+ breast cancers. 11, 12 However, 10-50% of ERα+ breast cancers contain a rare population of CK5+ cells. [7] [8] [9] 13 This CK5+ cell population is further enriched in ERα+ tumors of patients who have experienced recurrence following chemo or anti-estrogen therapies. 8, 13 In addition, in vitro and in vivo data indicate that the CK5+ cells display reduced sensitivity to adjuvant therapy and increased tumor-initiating potential, 8, 13 further supporting a role of CK5+ cells in the recurrence of ERα+ breast cancer. A series of reports have established that PR activation expands the CK5+ cell population in experimental models of ERα+ breast cancer. breast cancer is a unique effect of progestin (Prg) that is not mimicked by other steroids, including glucocorticoids. 19 The four members of the 3-ketosteroid receptor family bind to overlapping but distinct DNA response elements, are variably expressed in cell populations, and interact differentially with co-regulators, thus exerting both similar and distinct biological effects in breast cancer cells. [20] [21] [22] [23] Due to the wide use of glucocorticoids for a range of common conditions that frequently are comorbidities in patients with breast cancer, their administration at high doses with adjuvant chemotherapy to attenuate nausea and off-target toxicity, as well as their frequent use in metastatic cases for symptom management, we undertook a systematic analysis to determine whether 3-ketosteroids other than progesterone could expand the CK5+ cell population in ERα+ breast cancer.
The present study provides novel evidence that in ERα+ breast cancer several 3-ketosteroids, including glucocorticoids and mineralocorticoids, mimic Prg-induced expansion of therapyresistant CK5+ cells through a mechanism that requires the transcriptional repressor and oncogene BCL6. The data are supported by experimental studies of ERα+ breast cancer cell lines in vitro and in vivo. Further clinical significance is provided by the strong association between early disease recurrence and combined CK5 and BCL6 mRNA or protein expression levels in patients with ERα+ breast cancer.
RESULTS
Glucocorticoid and aldosterone mimic Prg induction of a CK5+ cell population in ERα+ breast cancer cell lines Cultured T47D and MCF7 cell lines were stimulated with cognate ligands for each of the four 3-ketosteroid receptor members, including dexamethasone (Dex), aldosterone (Ald), dihydrotestosterone (DHT) or Prg R5020, with 17β-estradiol (Est) and vehicle included as negative controls. Dex and Ald increased the CK5+ cell population in T47D and MCF7 cells four-to sevenfold as determined by flow cytometry (one-way analysis of variance (ANOVA), P o0.0001 for both analyses; Figure 1a Figure S1) . Dex-induced CK5+ cells in both T47D and MCF7 showed saturable dose responses consistent with receptor-mediated effects (Supplementary Figure S2) . Blockade of GR and PR by the combined receptor antagonist, mifepristone (RU486), selectively blocked the induction of CK5+ cells by Dex and Prg but not Ald in both cell lines, consistent with nuclear receptor-mediated induction of CK5 (two-way ANOVA, P o 0.0001 for both analyses; Supplementary Figure S3) . In T47D cultures, CK5+ cells increased over 6 days of Dex treatment and were preferentially expanded in clusters, with clusters containing ⩾ 4 cells increasing after 5 days (Supplementary Figure S4A-C) . Faster induction of CK5+ cells occurred in the more Dex-sensitive MCF7 line (Supplementary Figure S4D) , although induction of CK5 transcript levels was also rapid in T47D cells (Supplementary Figure S4E) .
Dex-and Ald-induced CK5+ cells display clonogenic and therapy-resistant properties To determine whether Dex-and Ald-induced CK5+ cells display stem/progenitor-like features similar to those reported for Prg-induced CK5+ cells, T47D cells pretreated with 3-ketosteroids were seeded in soft agar and colony formation was monitored. Treatment with either steroid induced a two-to threefold increase in colony number (one-way ANOVA, P o 0.0001) and a 1.5-to 2-fold increase in colony size (one-way ANOVA, P o 0.0001; Figure 2a-c) . Previous reports demonstrated that in vivo-derived Prg-induced CK5+ cells could be enriched based on their co-expression of the stem cell marker, CD44. 13, 15 Flow cytometry showed that CK5+ cells induced in T47D cell cultures by either Dex, Ald or Prg in vitro co-expressed CD44, with CK5+/CD44+ cells constituting 1.2% of cells in controls and 4.6, 11.0, and 3.9% in Dex-, Prg-and Ald-treated cultures, respectively (Figure 2d) .
Immunocytochemistry further showed that Dex-induced CK5+ breast cancer cells generally lack ERα and PR expression (Figure 3a) , similar to Prg-induced CK5+ cells. 13 Dex-or Aldinduced CK5+ cells were resistant to apoptosis as revealed by co-immunocytochemistry for CK5 and cleaved caspase-3 following pretreatment with Dex or Ald for 3 days and subsequent co-treatment with docetaxel (Doce) for 3 days. Image analysis of co-stained cultures demonstrated that cleaved caspase-3-positive cells (green) were significantly less likely to be CK5+ (red) in both Dex-treated (0.18% vs 0.01%; Paired samples t-test, P = 0.011) and Ald-treated (0.91% vs 0.05%; P = 0.005) cultures with virtually non-overlapping green and red pixels (Figure 3b and c) .
If Dex-induced CK5+ cells are less sensitive to drug-induced apoptosis, we expected that ERα+ cell lines pretreated with Dex, followed by Doce, doxorubicin or tamoxifen (Tam), would become enriched for CK5+ cells. Indeed, Dex-induced CK5+ cells were further enriched two-to threefold in T47D or MCF7 cell cultures following exposure to such adjuvant drugs (two-way ANOVA, Po 0.0001 for both cell lines; Figure 3d -f). Drug-induced expansion of the CK5+ cell population was also demonstrated in vivo as T47D xenograft tumors developed Tam resistance and showed marked enrichment of CK5+ cells relative to control tumors (P = 0.004; Figure 3g ; Supplementary Figure S5) . Collectively, we conclude that Dex-and Ald-induced CK5+ cells display reduced sensitivity to adjuvant agents, similar to that previously observed for Prg-induced CK5+ cells.
3-ketosteroid-induced CK5 expression in ERα+ breast cancer requires BCL6 We recesntly reported that Prgs upregulate BCL6 expression in several ERα+ breast cancer cell lines and that induction of BCL6 was required for Prg-induction of CK5+ cells. 16 As observed for Prg, western blots of whole-cell lysates revealed that BCL6 protein was frequently upregulated by Dex, Ald and DHT, but not Est, in ERα+ cell lines T47D, MCF7, BT474 and ZR75.1, but not in ERα − cell lines SKBr3 or MDA-MB-231 (Figure 4a (Figure 4c and d) . To determine whether 3-ketosteroids generally require BCL6 to induce the CK5+ cell population, two independent small hairpin RNAs in lentiviral vectors were used to knockdown expression of both basal and 3-ketosteroid-induced levels of BCL6 (two-way ANOVA, P o 0.0001; Figure 4e and f, Supplementary Figure S7 ). BCL6 knockdown abolished induction of CK5+ cells by Dex, Ald or Prg as determined by immunocytochemistry (two-way ANOVA, P o0.0001; Figure 4g and h).
As an independent strategy to test requirement of BCL6 for 3-ketosteroid induction of CK5, we used prolactin to suppress Representative images of fluorescence-based immunocytochemistry of T47D (e) and MCF7 (f) cell cultures following exposure to 3-ketosteroids for 6 days and stained for CK5 (red) and DAPI (blue).
BCL6 protein expression. Our lab and others have demonstrated that prolactin is capable of suppressing basal 24, 25 and Prg-induced levels of BCL6 protein in T47D cells. 16 following exposure to Doce, doxorubicin or Tam (two-way ANOVA, P o0.0001; Figure 5f and g). In contrast, epidermal growth factor co-stimulation was unable to suppress 3-ketosteroid induction of CK5 (Supplementary Figure S8B) . Furthermore, neither 3-ketosteroid induction of CK5 nor suppression by prolactin was detected in cultures of the hormone receptor-and prolactin receptor-negative 26 MDA-MB-231 breast cancer cell line (Supplementary Figure S8C) . Representative images of immunocytochemistry performed on T47D cells stimulated with 3-ketosteroids for 3 days following exposure to lentiviral-delivered shRNA against NTC or two independent BCL6 shRNAs for 60 h and stained for (e) BCL6 (red) and DAPI. Mean intensity of BCL6 protein expression in each field ± s.e.m. (f). Representative images of immunocytochemistry performed on T47D cells stimulated with 3-ketosteroids for 3 days following exposure to lentiviral-delivered shRNA against NTC or two independent BCL6 shRNAs for 60 h and stained for CK5 (red) and DAPI (g), with quantification of data expressed as percent area of CK5+ cells in each field ± s.e.m. (h). *P o0.05; **P o0.01; ***P o0.001; ****Po0.0001. expression (Figure 6a ), while not significantly impacting tumor size (Figure 6c ).
T47D
To determine whether prolactin treatment in vivo would suppress 3-ketosteroid induction of CK5+ cells, mice bearing T47D xenograft tumors were treated with or without high-dose MPA in the presence or absence of human prolactin for 18 days. Prolactin co-treatment effectively suppressed the induction of CK5+ cells by MPA (linear mixed model, Po0.0001) and attenuated MPA-induced levels of BCL6 (Figure 6d and e), consistent with our in vitro observations. Tumor size was not significantly affected (Figure 6f ).
Prolactin is therefore capable of attenuating 3-ketosteroid induction of BCL6 and CK5 in ERα+ breast cancer cells in vivo.
Quantification of CK5, BCL6 and GR protein expression across subtypes of breast cancer Using quantitative immunofluorescence analysis, we identified a significant number of clinically defined ERα+ breast cancers with elevated levels of CK5 expression. Based on the Tukey Box plot procedure,~10% of ERα+ primary breast cancer specimens Figure S9B) , indicating that reduction in ERα/PR levels is confined to the CK5+ subpopulation of cells within mixed ERα+/CK5+ tumors. CK5 expression combined with BCL6 expression in node-negative, ERα-positive breast cancer is associated with poor clinical outcome CK5 expression in TNBC breast cancer defines an aggressive and chemotherapy-resistant subtype, 6 but limited information is available on mosaic CK5 expression and clinical outcome in ERα+ breast cancer. As BCL6 expression is associated with CK5 expression, we hypothesized that combined quantitative data on CK5 and BCL6 expression will predict outcome in ERα+ breast cancer. We first used mRNA data from the publicly available Loi data set 29 that includes 170 ERα+, lymph node-negative patients, with 85 Tam-treated patients and 85 untreated patients. Remaining known patient characteristics are presented in Supplementary Table 2 . Recursive partitioning of cases based on quantitative levels of CK5 and BCL6 transcripts effectively separated favorable and poor prognostic groups (Figure 7b ; Supplementary Figure  S10A ) that remained highly significant after adjustment for other variables in multivariate survival analysis (hazard ratio (HR) 4.34; 95% confidence interval 2.06-18.39; P o 0.001; Table 1 ). Because mRNA levels often correlate poorly with protein levels, we examined BCL6 and CK5 protein levels in an independent cohort of 170 ERα+, lymph node-negative patients, with 50 patients (29.4%) receiving hormone therapy. Recursive partitioning of cases based on quantitative levels of CK5 and BCL6 protein also effectively distinguished favorable and poor prognostic groups (Figure 7c; Supplementary Figure S10B ) that remained highly significant after adjustment for other variables in multivariate survival analysis (HR 5.23; 95% confidence interval 1.89-16.37; P = 0.004; Table 1 ). The high-risk group in the mRNA-based analysis is made up of (1) high CK5 expression regardless of BCL6 levels, (2) the combination of low to moderate CK5 with moderate-to-high BCL6 and 3) low CK5 expression regardless of BCL6 levels. A similar pattern was found in protein analyses, with high risk associated with (1) high CK5 expression regardless of BCL6 levels, (2) high BCL6 in the absence of CK5 (l o 25%-tile of expression) and (3) the combination of low CK5 with low-tomoderate BCL6. Although ERα+ breast cancer with high CK5 and/or high BCL6 intuitively fit a mixed ERα+/CK5+ profile, the poor outcome in the fraction of ERα+ tumors with the very lowest CK5 levels most likely reflects the Luminal B subclass.
DISCUSSION
The present study documents a previously unrecognized ability of glucocorticoids and other 3-ketosteroids to expand a therapyresistant CK5+ cell population in breast cancer of the mixed ERα+/CK5+ subclass. This represents a paradigm shift in terms of the range of hormonal and pharmacological impact on mixed ERα+/CK5+ breast cancer beyond what was previously thought to be restricted to Prgs. 19 The discovery of glucocorticoid-driven expansion of the CK5+ cell population in mixed ERα+/CK5+ breast cancer is of particular clinical relevance considering (1) the widespread pharmacological use of glucocorticoids for common breast cancer comorbidities, (2) the standard administration of glucocorticoids to breast cancer patients who receive adjuvant chemotherapy and (3) stress-related elevation of endocrine glucocorticoids associated with a breast cancer diagnosis. Glucocorticoids have been implicated in resistance to chemotherapy in breast cancer as well as other solid tumors, [30] [31] [32] and stress-related elevation of endocrine glucocorticoids is associated with unfavorable clinical outcome in breast cancer patients. [33] [34] [35] [36] Although glucocorticoids may promote therapy resistance through multiple mechanisms, glucocorticoid-driven expansion of a de-differentiated and hormone receptor-negative CK5+ cell population may be particularly important for mixed ERα+/CK5+ breast cancer. As mineralocorticoid and androgen receptors are expressed in normal and malignant breast epithelia, 37, 38 further investigations of these 3-ketosteroids are warranted. Interestingly, a randomized Phase III study of ERα+ breast cancer patients on Tam revealed that co-treatment with the broad 3-ketosteroid MPA significantly worsened outcome. 39 Additional clinical significance for a 3-ketosteroid receptor-BCL6-CK5 pathway was provided by the discovery of a strong association between poor clinical outcome and elevated CK5/BCL6 expression in ERα+ breast cancer, associations that persisted in multivariate analyses with adjusted HRs much greater than those observed in limited reports of CK5 expression alone. 7, 9, 16 Thus, combining quantitative expression levels of CK5 and BCL6 may have diagnostic utility for ERα+ breast cancer.
Glucocorticoid-mediated effects on the CK5+ cell population were consistent with that seen following Prg stimulation for all readouts examined. The Dex-expanded CK5+ cell population was characterized by enrichment of stem cell marker CD44, loss of ERα expression, enhanced colony-forming ability in soft agar and broad therapy resistance against several classes of drugs, including the DNA-damaging agent doxorubicin, the microtubule disrupting agent Doce, and the selective ER modifier Tam. GR activation in mixed ERα+/CK5+ breast cancer also replicated Prg induction of oncoprotein and transcriptional repressor BCL6 [40] [41] [42] prior to expansion of the CK5+ cell population. Upregulation of BCL6 was required for CK5+ cell expansion by glucocorticoids, Ald and Prgs based on BCL6 knockdown and effective downregulation of BCL6 protein by prolactin. The results were validated in vivo by the demonstration that T47D xenograft tumors grown in 3-ketosteroid-treated mice displayed markedly elevated BCL6 protein accompanied by expansion of the CK5+ cell population, effects that were blocked by prolactin. Our data therefore indicate that the 3-ketosteroid nuclear receptor family shares a common mechanism for CK5+ cell induction in mixed ERα+/CK5+ breast cancer that involves upregulation of BCL6. Future studies will investigate three predicted glucocorticoid response elements (UCSC Genome Browser) in the BCL6 gene promoter and five in 43 and BCL6 is elevated in high-grade and metastatic breast cancers. 24, 25, 44 Follow-up studies will determine whether BCL6 upregulation alone is sufficient for expansion of the CK5+ cell population in tumors of the mixed ER+/CK5+ subtype, and will seek to extend the mechanistic studies from laboratory cell lines to patient-derived xenograft models and murine genetic models.
The efficacy of prolactin to abrogate expansion of the de-differentiated CK5+ cell population induced by 3-ketosteroids or chemo-and anti-estrogen therapies in ERα+ breast cancer is intriguing, but is consistent with the established role of prolactin in the maintenance of mammary epithelial differentiation. [45] [46] [47] [48] Loss of prolactin signaling may potentiate the emergence of this CK5+/ERα − cell population in a subgroup of ERα+ breast cancers through unopposed BCL6 activity and lead to therapy resistance. Loss of signaling by signal transducer and activator of transcription-5 (STAT5), a key mediator of prolactin signaling, is associated with poor clinical outcome and increased risk of failure of antiestrogen therapy. 45, 46, 49, 50 Although prolactin receptor expression is typically maintained or increased in breast cancer 51 and may be further boosted by co-recruitment of Jak1 in addition to Jak2, 26 disruptive mechanisms underlying observed frequent loss of prolactin receptor signaling include extracellular acidosis, 52 elevated levels of the Jak2 phosphatase PTP1B 53 or loss of STAT5a protein expression or phosphorylation. 50 Suppression of prolactin signaling is potentially of particular relevance for mixed ERα+/CK5+ breast cancer. These observations shed new light on evidence that prolactin-STAT5 signaling inhibits invasive features and maintains cell differentiation of some ERα+ breast cancer lines. 48, 54 In conclusion, the new data broadly implicate receptors for 3-ketosteroids as drivers of expansion of the therapy-resistant CK5+ cell population in mixed ERα+/CK5+ breast cancer. A common mechanism involves upregulation of the transcriptional repressor BCL6. The progress supports the concept that mixed ERα+/CK5+ breast cancers develop resistance to anti-estrogens and chemotherapies driven by selective expansion of a CK5+/ERα − subpopulation of cells. The observations provide rationale for exploring 3-ketosteroid receptor antagonists or BCL6 inhibitors in patients with mixed ERα+/CK5+ breast cancer. Conversely, progression of mixed ERα+/CK5+ breast cancer may be promoted by pharmacological agonists of 3-ketosteroid receptors or physiological or pathophysiological conditions (for example, stress, pregnancy and endocrinopathies) that elevate 3-ketosteroids. Finally, loss of prolactin-STAT5 signaling may directly contribute to progression of mixed ERα+/CK5+ breast cancer.
MATERIALS AND METHODS

Cell culture
Cell lines were cultured as previously described. 16, 55 Media were changed to RPMI+5% charcoal-stripped fetal calf serum (Thermo Scientific, Philadelphia, PA, USA) 24 h before experiments. Cells were treated with 20 nM recombinant human prolactin (AFP795; National Hormone and Peptide Program, Torrance, CA, USA), 1-10 μM Dex, 100 nM Ald, 10 nM DHT, 1 nM 17β-Est, 10 nM epidermal growth factor (Sigma, St Louis, MO, USA), 20 nM R5020 (PerkinElmer, Waltham, MA, USA), and/or 1 μM RU486 (Sigma) as indicated with fresh media every 3 days. Dex was applied at 1 μM for MCF7 and 10 μM for T47D, as determined by dose response experiments. For adjuvant therapy experiments, cells were treated with hormones for 3 days before treatment with 10 nM Doce, 1 μM doxorubicin, or 1 nM 17β-Est+1 nM 4-Hydroxytamoxifen (Sigma) for 3 days. Cell lines were obtained from ATCC (authenticated by Short Tandem Repeat profiling and confirmed mycoplasma-negative) and cultured for o6 months.
Lentiviral infection
Lentivirus was produced as described previously. 16 Cells were infected with lentivirus overnight and allowed to grow for 48 h before hormone induction for an additional 6 days.
Quantitative reverse transcription PCR
Quantitative reverse transcription PCR assays were performed as described previously 16, 24 using corresponding primers (Supplementary Table S1 ).
Immunoblotting
Performed as described previously. 53 Proteins were immunoblotted with antibodies to phospho-STAT5 (#611964; BD Biosciences, East Rutherford, NJ, USA), total STAT5 (#610192; BD Biosciences), BCL6 (#M7211; Dako, Carpinteria, CA, USA), CK5 (#MS-1896-S; Thermo Scientific) or GAPDH (sc-25778; Santa Cruz Biotechnology, Dallas, TX, USA), followed by AlexaFluor-680-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) or IRDye-800-CW-conjugated goat anti-rabbit IgG (Licor, Lincoln, NE, USA). Immunoblots were scanned using Odyssey Infrared Imaging System (Licor).
Immunocytochemistry
Performed as described previously. 16 Primary antibodies to BCL6, CK5, ERα (EP1; Dako), PR-B (#3157S; Cell Signaling, Beverly, MA, USA), GR (#3660; Cell Signaling), GATA3 (#5852S; Cell Signaling) or Cleaved Caspase-3 (#9661; Cell Signaling) were applied, followed by AlexaFluor-555-conjugated goat anti-mouse/488-conjugated goat anti-rabbit antibodies (Invitrogen). Images were captured using the OLY-100 microscope.
Flow cytometry
Cells were collected, fixed, permeabilized and stained with FITCconjugated CK5 antibody (sc-32721; Santa Cruz Biotechnology) and/or PE-conjugated CD44 (#562818; BD Biosciences), run on a BD LSRII instrument, and analyzed by FlowJo (Ashland, OR, USA). The CK5+ gate was defined for 1% of vehicle cells as positive and applied to each specimen.
Soft agar assay T47D cells were pretreated for 6 days and allowed to form colonies in soft agar for 3 weeks. 10 images/well were analyzed using ImageJ software (NIH, Bethesda, MD, USA) for number and mean size of colonies 4600 pixels.
Xenograft studies T47D xenotransplants were performed in immunodeficient estrogenized nude female mice (8-10 weeks old, 17β-Est pellets; 0.72 mg/90 days release; IRA, Sarasota, FL, USA) as described previously. 24 For the Tam study, tumors growing in control-treated (n = 5) or Tam-treated mice (n = 5; 10 mg/90 days release; IRA) were harvested as indicated. For the Dex/MPA studies, mice (n = 21) were randomized and implanted with Dex (1.5 mg/ 60 days) or MPA (10 mg/60 days) subcutaneous pellets. Specified randomized animals (n = 6) were injected subcutaneously with 4 μg/g body mass of human prolactin biweekly for 3 weeks. Tumors from animals that died were excluded from the analysis. All animal studies were approved by Thomas Jefferson University's IACUC.
Immunohistochemistry
Performed as described previously. 16, 24 Tumor sections were stained with CK5 and BCL6, and images were taken at 20-40 × magnification using the Olympus BX40 microscope and analyzed for percent area of CK5+ cells in a blinded manner. A breast cancer tissue microarray representing an unselected cohort of patients from Thomas Jefferson University Hospital pathology archives under Institutional Review Board-approved protocols was evaluated for nuclear or cytoplasmic BCL6, CK5, ER (#M7047; Dako), AR (#MDR2044; Molecular Detection and Retrieval, Windber, PA, USA), PR (#M3569; Dako), Her2 (#A0485; Dako) and GR immunofluorescent staining on 276 cases using an Autostainer Plus (Dako). High-resolution digital images were captured at 20 × using Scanscope FL (Aperio, Sausalito, FL, USA). Quantitative analyses for average staining intensity were performed using Tissue Studio digital pathology image analysis software (Definiens, Carlsbad, CA, USA).
Statistical methods
Appropriate statistical analyses, post hoc tests and Bartlett's test for equal variance were performed using R (R Foundation for Statistical Computing, Vienna, Austria), SPSS (IBM, Armonk, NY, USA) and GraphPad Prism software (Graphpad Software, La Jolla, CA, USA). All in vitro experiments presented are representative and were replicated at least two times. Data presented in bar graphs represent mean (n = 3) ± s.e.m. Sample sizes for relevant experiments were determined by power analyses conducted during experiment planning. CK5 and BCL6 mRNA expression data and clinical annotations from Loi et al. 29 were downloaded from the GeneChip Oncology Database, which contained Affymetrix HG-U133A expression data for ERα+, lymph node-negative breast cancers with focus on relapsefree survival and data from the BCL6 (X203140_at, X215990_s_at) and CK5 (X201820_at) probes. A breast cancer array with clinical annotation from Thomas Jefferson University Hospital pathology archives focusing on ERα+, lymph node-negative patients was developed and protein expression of BCL6 and CK5 was quantified from immunofluorescent staining analyzed by Tissue Studio (Definiens Inc, Munich, Germany). For each cohort, a recursive partitioning analysis 56 of BCL6 and CK5 expression data were performed to determine marker combinations informative of relapse-free survival, which was then incorporated in a multivariable Cox model controlled for age at diagnosis, hormone therapy status, grade and tumor size in the mRNA model, and age at diagnosis, hormone therapy status and stage in the protein model. Bootstrap was completed around the recursive partitioning and Cox modeling process. Confidence intervals and P-values for adjusted HRs are reported based on 2000 bootstrap samples. The R packages, rpart, survival and bootstrap were used to complete survival analysis.
